Dear Reader,Our scanners just identified several healthtech stocks that are expected to release earnings starting, February 7th.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
23andMe Holding
Symbol: ME
Recent Price: $2.6
Average Analyst Price Target: $6.50 (150.00%)
Market Cap: $1.23B
Last Year's EPS: -$0.21
Consensus EPS Forecast: -$0.19
Expected Earnings Date: Feb 07 2023
Recent Analyst Action: Gaurav Goparaju, analyst at Berenberg Bank, reiterates coverage on 23andMe Holding (ME) in the Healthcare sector with a Buy rating and a price target of $ 7 (1 month ago).
TipRanks.com also reports that 23andMe Holding currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.50 . The target pricing ranges from a high forecast of $7.00 down to a low forecast of $6.00. 23andMe Holding (ME)’s last closing price was $2.6 which would put the average price target at 150.00% upside.Here are 3rd party ratings for ME:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: n/a
--------------------------------------------------------------------------
Atara Biotherapeutics
Symbol: ATRA
Recent Price: $5.4
Average Analyst Price Target: $20.33 (276.48%)
Market Cap: $490.52M
Last Year's EPS: -$0.96
Consensus EPS Forecast: -$0.55
Expected Earnings Date: Feb 27 2023
Recent Analyst Action: Salim Syed, analyst at Mizuho Securities, reiterates coverage on Atara Biotherapeutics (ATRA) in the Healthcare sector with a Buy rating and a price target of $ 31 (22 hours ago).
TipRanks.com also reports that Atara Biotherapeutics currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $20.33 . The target pricing ranges from a high forecast of $31.00 down to a low forecast of $5.00. Atara Biotherapeutics (ATRA)’s last closing price was $5.4 which would put the average price target at 276.48% upside.Here are 3rd party ratings for ATRA:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 37% (92 out of 250)
--------------------------------------------------------------------------
Azenta
Symbol: AZTA
Recent Price: $57.22
Average Analyst Price Target: $70.50 (23.21%)
Market Cap: $4.03B
Last Year's EPS: $0.12
Consensus EPS Forecast: n/a
Expected Earnings Date: May 02 2023
Recent Analyst Action: Vijay Kumar, analyst at Evercore ISI, reiterates coverage on Azenta (AZTA) in the Healthcare sector with a Hold rating and a price target of $ 62 (1 month ago).
TipRanks.com also reports that Azenta currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $70.50 . The target pricing ranges from a high forecast of $78.00 down to a low forecast of $62.00. Azenta (AZTA)’s last closing price was $57.22 which would put the average price target at 23.21% upside.Here are 3rd party ratings for AZTA:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 36% (161 out of 250)
--------------------------------------------------------------------------
Envista Holdings
Symbol: NVST
Recent Price: $40.82
Average Analyst Price Target: $45.00 (10.24%)
Market Cap: $6.72B
Last Year's EPS: $0.46
Consensus EPS Forecast: $0.49
Expected Earnings Date: Feb 07 2023
Recent Analyst Action: Jason Bednar, analyst at Piper Sandler, reiterates coverage on Envista Holdings (NVST) in the Healthcare sector with a Buy rating and a price target of $ 46 (22 hours ago).
TipRanks.com also reports that Envista Holdings currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $45.00 . The target pricing ranges from a high forecast of $46.00 down to a low forecast of $44.00. Envista Holdings (NVST)’s last closing price was $40.82 which would put the average price target at 10.24% upside.Here are 3rd party ratings for NVST:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Bottom 38% (154 out of 250)
--------------------------------------------------------------------------
Innoviva
Symbol: INVA
Recent Price: $12.71
Average Analyst Price Target: $13.00 (2.28%)
Market Cap: $893.22M
Last Year's EPS: $0.14
Consensus EPS Forecast: $0.23
Expected Earnings Date: Feb 07 2023
Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on Innoviva (INVA) in the Healthcare sector with a Sell rating and a price target of $ 13 (1 week ago).
TipRanks.com also reports that Innoviva currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Sell rating with an average price target is $13.00 . The target pricing ranges from a high forecast of $13.00 down to a low forecast of $13.00. Innoviva (INVA)’s last closing price was $12.71 which would put the average price target at 2.28% upside.Here are 3rd party ratings for INVA:
- TipRanks.com: Moderate Sell
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Strong Sell, Bottom 29% (177 out of 250)
--------------------------------------------------------------------------
Invacare
Symbol: IVC
Recent Price: $0.66
Average Analyst Price Target: $2.00 (202.98%)
Market Cap: $1.36M
Last Year's EPS: $0.08
Consensus EPS Forecast: -$0.24
Expected Earnings Date: Feb 07 2023
Recent Analyst Action: Matt Nirenberg, analyst at Oppenheimer, reiterates coverage on Invacare (IVC) in the Healthcare sector with a Buy rating and a price target of $ 2 (2 months ago).
TipRanks.com also reports that Invacare currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $2.00 . The target pricing ranges from a high forecast of $2.00 down to a low forecast of $2.00. Invacare (IVC)’s last closing price was $0.66 which would put the average price target at 202.98% upside.Here are 3rd party ratings for IVC:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: n/a
--------------------------------------------------------------------------
Kamada
Symbol: KMDA
Recent Price: $4.51
Average Analyst Price Target: $11.00 (143.90%)
Market Cap: $211.13M
Last Year's EPS: -$0.03
Consensus EPS Forecast: $0.04
Expected Earnings Date: Feb 07 2023
Recent Analyst Action: Andrew Fein, analyst at H.C. Wainwright, reiterates coverage on Kamada (KMDA) in the Healthcare sector with a Buy rating and a price target of $ 11 (2 months ago).
TipRanks.com also reports that Kamada currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $11.00 . The target pricing ranges from a high forecast of $11.00 down to a low forecast of $11.00. Kamada (KMDA)’s last closing price was $4.51 which would put the average price target at 143.90% upside.Here are 3rd party ratings for KMDA:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: hold
- Zacks.com: n/a
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
